Unite2Cure meets with Glenis Wilmott, MEP

Unite2Cure meeting with

From left to right: Chris Copland, Consumer Representative, National Cancer Research Institute – Pam Kearns, Director of the Cancer Research UK Clinical Trials Unit – Glenis Wilmott, MEP – Karen and Kevin Capel, Christopher’s Smile – Catherine Guinard, Public affairs Manager, CRUK

A team of Unite2Cure representatives met on Friday January 15th with MEP Glenis Wilmott, who has been actively involved in promoting changes to the Paediatric Medicines Regulation (PMR) in order to speed up the development of new drugs for kids with cancer.
Ms. Wilmott was able to provide some insight into the legislative process, but in particular, what MEPs can do to push the process forward. It is clear that what is required is a straightforward and relatively simple proposal on changes to the PMR. Framing something of this kind will be our goal during the Cancer Drug Development Forum (CDDF) congress this week in Brussels. It was also agreed that ideally a balanced set of proposals with toughening up of requirements on mechanism of action combined with some new incentives on the lines of those framed by WG2 would appear attractive.

 

September: International Childhood Cancer Awareness Month

To coincide with International Childhood Cancer Awareness month in September Unite2Cure is calling for immediate change to current European Legislation. This campaign is being supported by doctors and other industry experts across Europe. For a list of supporters and to join our conversation click here!

Some Facts…

It is impossible to measure the impact that childhood cancer has on it’s victims and their families by using statistics but research funding decisions are often based on numbers. Here are some facts about childhood cancer for you to consider:

• Cancer is the leading cause of death by disease in children in Europe.

• Each year in Europe, over 35,000 kids and teenagers are diagnosed with cancer.

• One out of roughly every 300 children will develop cancer before their 20th birthday.

• Approximately 25 percent of all children with cancer will die from their disease, a secondary cancer, or complications from treatment.

• The causes of most pediatric cancers remain a mystery and cannot be prevented.

• Childhood cancer does not discriminate, sparing no ethnic group, socio-economic class or geographic region.

• About one in 600 young adults is a childhood cancer survivor. Nearly 2/3 of the survivors later experience significant and chronic medical problems or develop secondary cancers as adults that result from the treatment of their original cancer.

• The average age of death for a child with cancer is 8, causing a childhood cancer victim to lose 69 years of expected life years; a significant loss of productivity to society.